Government Vaccine Supply Contract
Panacea Biotec Wins ₹20.79 Cr Government Vaccine Supply Order
NSE
panaceabio
BSE
531349
Panacea Biotec Limited has received a Letter of Award (LOA) from the Central Medical Services Society (CMSS) for the supply of Diphtheria and Tetanus (Td) vaccines. The order, valued at ₹20.79 crore, will be executed over multiple tranches till 2028.
PRICE-SENSITIVE TRIGGER
Event: Order Win (LOA Received)
Type: Government Vaccine Supply Contract
Impact: Positive
Immediate Effect: Adds to order book and revenue visibility
Key Metrics
- Order Value: ₹20.79 Crore
- Product: Td Vaccine (Diphtheria & Tetanus)
- Client: Central Medical Services Society (CMSS), Govt. of India
- Execution Period: Sept/Oct 2026 to Nov/Dec 2028
Highlights
Multi-year government vaccine supply contract secured
What Happened ?
Panacea Biotec Limited announced that it has received a Letter of Award from CMSS under the Ministry of Health & Family Welfare.
The contract involves supply of Td vaccines for adults and adolescents in phased manner.
Details Breakdown
Order Details
- Client: CMSS (Government of India)
- Nature: Supply of Td Vaccine
- Category: Domestic government contract
Execution Timeline
- Start: September / October 2026
- End: November / December 2028
- Multi-tranche supply
Business Significance
- Strengthens presence in public healthcare supply chain
- Provides long-term revenue visibility
- Enhances credibility in vaccine segment
Risk Analysis
Key Risks
- Execution delays in supply chain
- Dependence on government procurement cycles
- Pricing and margin pressure in public contracts
Worst Case Scenario
Delays or cancellations could impact expected revenue realization.
Risk Level: Medium
Company Commentary
- LOA received from CMSS
- Supply to be executed in multiple tranches
- No related party involvement
Official Exchange Filing: Panacea Biotec Limited